Physician profile
Michael Mitchell
NPI 1548298045
$2,215.42
in general payments reported to CMS, 2019-2025
22 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $171 · 2022: $82.85 · 2023: $803 · 2024: $653 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,029.49 | 2019-2023 | Xeomin |
| Lexicon Pharmaceuticals, INC. | $145.76 | 2024 | Inpefa |
| Merck Sharp & Dohme LLC | $114.19 | 2024-2025 | Verquvo |
| Medtronic, INC. | $98.60 | 2025 | Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $83.03 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.29 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $75.39 | 2024 | Arcalyst |
| Abbott Laboratories | $75.03 | 2023-2025 | Coroflow, Xience Skypoint, Mitraclip |
| Novartis Pharmaceuticals Corporation | $72.83 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.11 | 2024-2025 | Camzyos, Eliquis |
| Pfizer INC. | $63.22 | 2024 | |
| Amgen INC. | $62.54 | 2023-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $53.00 | 2024 | |
| Philips North America LLC | $35.31 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Janssen Pharmaceuticals, INC | $33.44 | 2024 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $22.06 | 2025 | Opsynvi, Uptravi |
| Scpharmaceuticals INC. | $20.53 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.99 | 2023 | Lifevest |
| Ironshore Pharmaceuticals INC. | $17.15 | 2024 | |
| Cardiva Medical, INC. | $16.96 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Vifor Pharma, INC. | $16.58 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.